Prosensa (NASDAQ: RNA) is one of 5 public companies in the “Biotechnology & Medical Research – NEC” industry, but how does it weigh in compared to its peers? We will compare Prosensa to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.
Earnings and Valuation
This table compares Prosensa and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Prosensa Competitors||$1.34 billion||$80.40 million||-262.46|
Insider & Institutional Ownership
62.1% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by institutional investors. 9.0% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of recent recommendations for Prosensa and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology & Medical Research – NEC” companies have a potential upside of 41.44%. Given Prosensa’s peers higher possible upside, analysts plainly believe Prosensa has less favorable growth aspects than its peers.
This table compares Prosensa and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Prosensa peers beat Prosensa on 6 of the 8 factors compared.
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. The Company’s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company’s platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Receive News & Ratings for Prosensa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prosensa and related companies with MarketBeat.com's FREE daily email newsletter.